TT genotype of GNAS1 T393C polymorphism predicts better outcome of advanced non-small cell lung cancer patients

Table 1 Clinicopathological characteristics of 94 patients with non-small cell lung cancer

	Subgroup	n	MST	1-yr OS (%)	2-yr OS (%)	P
Gender	Male	71	14	59	36	0.058
	Female	23	13	53	28
Age	≥ 60 yr	51	13	61	26	0.135
	< 60 yr	43	16	52	36
PS	≥ 2	25	13	51	25	0.658
	< 2	69	17	64	32
Smoking	Yes	23	13	55	29	0.473
	No	71	14	58	32
Pathology	Adenocarcinoma	48	13	54	36	0.559
	Squamous cell carcinoma	46	14	63	29
Treatment	Supportive treatment only	12	10	49	25	0.116
	Chemotherapy	14	13	56	32
	Radiotherapy	11	13	60	30
	Chemoradiotherapy	57	16	64	35
GNAS1 T393C	TT	38	25	76	48	0.01
	TC	29	12	54	18
	CC	27	8	23	15
	TC + CC	56	11.5	25	16	0.01

OS: Overall survival; PS: Performance status.

Table 2 Association between GNAS1 T393C single nucleotide polymorphism and clinical parameters

	Subgroup	All (n = 94)	TT (n = 38; 40%)	TC (n = 29; 31%)	CC (n = 27; 29%)	P
Gender	Male	71	31 (43.6)	22 (30.9)	18 (25.5)	0.42
	Female	23	7 (30.4)	7 (30.4)	9 (39.2)
Age	≥ 60 yr	51	22 (43.1)	13 (25.5)	16 (31.4)	0.48
	< 60 yr	43	16 (37.2)	16 (37.2)	11 (25.6)
Performance status	≥ 2	25	13 (52.0)	5 (20.0)	7 (28.0)	0.30
	< 2	69	25 (36.2)	24 (34.8)	20 (29.0)
Smoking	Yes	23	12 (52.2)	6 (26.1)	5 (21.7)	0.44
	No	71	26 (36.6)	23 (32.4)	22 (31.0)
Pathology	Adenocarcinoma	48	19 (39.6)	17 (35.4)	12 (25.0)	0.59
	Squamous cell carcinoma	46	19 (41.3)	12 (26.1)	15 (32.6)

Table 3 The effect of GNAS1 T393C on distinct carcinomas

Author	Year	Cancer type	All	Genotype	n	OS (%)	Benefit	P
Alakus	2009	Gastric cancer	122	TT	26	56.9	TT	0.043
				TC	57	32.7
				CC	39	42.6
Schmitz	2007	Cholangiocarcinoma	87	TT	15	10	C+	0.04
				TC	41	17
				CC	31	18
Lehnerdt	2008	Laryngocarcinoma	157	TT	40	76	TT	0.037
				TC	75	49
				CC	42	43.5
Frey	2006	Chronic lymphocytic leukemia	144	TT	27	73	T+	0.013
				TC	72	63.3
				CC	45	33.2
Vashist	2011	Esophageal cancer	190	TT	38	19	CC	0.001
				TC	96	15
				CC	56	51
Frey	2005	Bladder cancer	254	TT	49	82	TT	0.015
				TC	121	60
				CC	84	58
Frey	2006	Renal cancer	150	TT	34	91	TT	0.01
				TC	79	81
				CC	37	69
Frey	2005	Colorectal cancer	151	TT	36	87.8	TT	0.009
				TC	72	71
				CC	43	50
Otterbach	2007	Breast cancer	279	TT	64	23	CC	0.01
				TC	162	40
				CC	53	63
Lehnerdt	2008	Oral carcinoma	202	TT	48	51.3	TT	0.015
				TC	89	44.7
				CC	65	36.8
Kaderi	2008	Chronic lymphocytic leukemia	279	TT	80	65	NS	0.802
				TC	115	70
				CC	84	64
Frey	2010	Malignant melanoma	328	TT	69	87.1	TT	0.017
				TC	149	NS
				CC	110	66
Xie	2013	Non-small cell	131	TT	33	NS	TT	0.02
		lung cancer		TC	63	NS
				CC	35	NS

OS: Overall survival.